Home » Topics » Disease categories and therapies » Urology

Urology
RSS

FDA committee votes in favor of approving SER-120 for nocturia

Oct. 24, 2016

FDA accepts NDA resubmission for sodium zirconium cyclosilicate

Oct. 18, 2016

Omeros reports phase II data for OMS-721, pursuing FDA breakthrough therapy designation

Oct. 18, 2016

Phase II results lead NeuroVive to discontinue development of CicloMulsion for acute kidney injury

Oct. 13, 2016

Takeda Pharmaceutical presents EIT6 inhibitors

Oct. 13, 2016

Xenetic Biosciences reports positive data from phase II trial of erepoxen

Oct. 11, 2016

JW Pharmaceutical reports desfesoterodine derivatives

Oct. 10, 2016

Toray Industries prepares and tests agents for urinary incontinence

Oct. 6, 2016

FDA grants orphan drug designation to AbbVie's atrasentan

Oct. 5, 2016

Dimerix reports positive safety data for phase II trial of DMX-200

Oct. 5, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 27, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
In the clinic for May 26, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: 858, A2 Biotherapeutics, AC Immune, Agendia, Agenus, Aktis, Ascentage,...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...